Belluscura (LSE:BELL) Stock Based Compensation: £0.06 Mil (TTM As of Jun. 2024)


What is Belluscura Stock Based Compensation?

Belluscura LSE:BELL Stock Based Compensation is £0.06 Mil as of Jun. 2024.

Belluscura's Stock Based Compensation for the six months ended in Jun. 2024 was £0.03 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2024 was £0.06 Mil.

Belluscura Stock Based Compensation Related Terms

Belluscura Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Belluscura's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Belluscura Stock Based Compensation Chart

Belluscura Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Stock Based Compensation
Get a 7-Day Free Trial 0.01 0.08 0.14 0.19 0.11

Belluscura Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.11 0.07 0.08 0.03 0.03

Belluscura Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.06 Mil.

What does a Stock Based Compensation of £0.06 Mil mean?
Belluscura (LSE:BELL) has a Stock Based Compensation of £0.06 Mil as of Jun. 2024. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Belluscura and its competitors.
Is Belluscura's Stock Based Compensation too high?
Belluscura's current Stock Based Compensation is £0.06 Mil.
How does Belluscura's Stock Based Compensation compare to ABT and BSX?
Belluscura's Stock Based Compensation of £0.06 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Medical Devices & Instruments company?
A good Stock Based Compensation depends on the Medical Devices & Instruments industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Belluscura and its competitors. Belluscura's current Stock Based Compensation is £0.06 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Belluscura stock overvalued right now?
Belluscura (LSE:BELL) has a current Stock Based Compensation of £0.06 Mil. The current Stock Based Compensation is £0.06 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Belluscura (LSE:BELL), the current Stock Based Compensation is £0.06 Mil as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Belluscura Business Description

Address 15 Fetter Lane, Holborn, London, GBR, EC4A 1BW
Belluscura PLC is a medical device company. Its first product, the X-PLOR, is a lightweight FDA-cleared portable oxygen concentrator designed to replace larger, metal oxygen tanks and heavier portable oxygen concentrator devices. The company has only one operating segment being the sale of oxygen concentrators in the United States. The X-PLO2R weighs less than 1.5kg (3.25 lbs) and it is the first modular portable oxygen concentrator it will generate more oxygen by weight than any other FDA-cleared POC in its class. It either owns or exclusively licenses a total of 26 patents and applications relating to oxygen enrichment devices and treatments.